Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO (RELAX)
An Observational Study to Evaluate the Real-world Experience of Patients Who Are Initiating Treatment With Telotristat Ethyl (XERMELO™)
Sponsor: TerSera Therapeutics LLC
This observational or N/A phase trial investigates Carcinoid Syndrome and is currently completed. TerSera Therapeutics LLC leads this study, which shows 10 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Aug 2024 — Sep 2024 [monthly]
Completed
-
Jul 2024 — Aug 2024 [monthly]
Completed
-
Mar 2022 — Jul 2024 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Nov 2021 — Mar 2022 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
▶ Show 5 earlier versions
-
Jan 2021 — Nov 2021 [monthly]
Recruiting
-
Oct 2020 — Jan 2021 [monthly]
Recruiting
-
Sep 2019 — Oct 2020 [monthly]
Recruiting
-
Apr 2018 — Sep 2019 [monthly]
Recruiting
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Recruiting NA
First recorded
Jun 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- TerSera Therapeutics LLC
For direct contact, visit the study record on ClinicalTrials.gov .